Akums Drugs & Pharmaceuticals Ltd Hits Intraday High with 9.62% Surge

Intraday Trading Highlights

On 16 Feb 2026, Akums Drugs & Pharmaceuticals Ltd demonstrated strong buying momentum, touching an intraday peak of Rs 487.2, which represents an 8.11% increase from its previous close. The stock closed the day with a 9.62% gain, substantially outperforming the Pharmaceuticals & Biotechnology sector by 6.83% and the Sensex benchmark, which rose by a modest 0.26%.

The stock’s recovery followed two consecutive days of declines, signalling a trend reversal. It traded above its 5-day, 20-day, 50-day, and 100-day moving averages, indicating short- to medium-term strength. However, it remained below the 200-day moving average, suggesting some longer-term resistance.

Market Context and Sector Comparison

The broader market environment on 16 Feb 2026 was characterised by a positive turnaround in the Sensex. After opening 146.36 points lower, the index rebounded by 363.47 points to close at 82,843.87, up 0.26%. Despite this recovery, the Sensex remained approximately 4% below its 52-week high of 86,159.02. Mega-cap stocks led the market gains, while the index traded below its 50-day moving average, though the 50DMA itself was positioned above the 200DMA, signalling a cautiously optimistic market trend.

Within this context, Akums Drugs & Pharmaceuticals Ltd’s 9.62% gain stands out as a strong outperformance. The stock’s one-day performance of 9.83% notably eclipsed the Sensex’s 0.26% rise, underscoring its relative strength in the Pharmaceuticals & Biotechnology sector.

Performance Trends Over Various Timeframes

Akums Drugs & Pharmaceuticals Ltd’s recent price action reflects a strong recovery trend. Over the past week, the stock gained 5.94%, contrasting with the Sensex’s 1.45% decline. The one-month performance shows an 11.49% increase against the Sensex’s 0.87% fall, while the three-month gain stands at 16.62%, outperforming the Sensex’s 2.03% drop.

Year-to-date, the stock has risen 9.09%, significantly ahead of the Sensex’s 2.79% decline. However, over the one-year horizon, Akums Drugs & Pharmaceuticals Ltd’s price is down 6.05%, lagging the Sensex’s 9.09% gain. The stock’s three-, five-, and ten-year performances remain flat at 0.00%, compared to the Sensex’s substantial long-term gains of 35.10%, 59.00%, and 257.21% respectively.

Mojo Score and Market Capitalisation Insights

The company holds a Mojo Score of 34.0, categorised as a Sell grade as of 17 Nov 2025, an improvement from its previous Strong Sell rating. This upgrade reflects a positive shift in the stock’s momentum and quality metrics, although it remains below the threshold for a Buy rating. The market capitalisation grade stands at 3, indicating a modest market cap relative to peers in the Pharmaceuticals & Biotechnology sector.

Summary of Trading Activity and Technical Positioning

Akums Drugs & Pharmaceuticals Ltd’s intraday high of Rs 487.2 and closing gain of 9.62% on 16 Feb 2026 highlight a day of strong buying interest and technical recovery. The stock’s position above multiple short- and medium-term moving averages supports the current upward momentum, although the 200-day moving average remains a key resistance level to monitor in subsequent sessions.

The stock’s outperformance relative to the sector and Sensex benchmarks underscores its current strength within the Pharmaceuticals & Biotechnology space. The recent upgrade in Mojo Grade from Strong Sell to Sell further reflects an improving trend in the company’s market metrics and investor sentiment.

Overall, the trading session on 16 Feb 2026 marks a significant rebound for Akums Drugs & Pharmaceuticals Ltd, with the stock demonstrating resilience and a notable intraday surge that outpaced broader market gains.

Unlock special upgrade rates for a limited period. Start Saving Now →